Advisory Service咨询服务
Tax planning, corporate structuring, and financial advisory for enterprises importing FDA-regulated products into the US market. 为将 FDA 监管产品进口到美国市场的企业提供税务筹划、公司架构和财务咨询。
Chinese manufacturers and Asia-Pacific enterprises exporting FDA-regulated products to the US face a dual compliance burden: meeting FDA regulatory requirements and navigating the complex tax and corporate structure implications that come with establishing a US market presence. 中国制造商和亚太企业向美国出口 FDA 监管产品时面临双重合规负担：既要满足 FDA 监管要求，又要应对建立美国市场存在所带来的复杂税务和公司架构问题。
Most firms handle FDA compliance and financial planning in silos. FDA consultants don’t understand transfer pricing. Tax advisors don’t understand FSMA or 510(k) cost structures. This disconnect leads to inefficient entity designs, missed tax benefits, and compliance gaps that surface during audits. 大多数企业将 FDA 合规和财务规划分开处理。FDA 顾问不了解转让定价，税务顾问不了解 FSMA 或 510(k) 成本结构。这种脱节导致实体设计低效、错失税收优惠，以及审计时才暴露的合规漏洞。
We bridge the gap between FDA regulatory compliance and cross-border financial planning. Our team understands both the regulatory landscape—510(k), PMA, ANDA, FSMA, MoCRA—and the tax and structuring implications for enterprises operating across the US-China-HK-Singapore corridor. 我们弥合 FDA 监管合规与跨境财务规划之间的鸿沟。团队同时理解监管环境——510(k)、PMA、ANDA、FSMA、MoCRA——以及在美中港新走廊运营企业的税务和架构影响。
Every engagement produces an integrated plan: the right US entity structure for FDA compliance, optimized for tax efficiency, with clear financial projections for market entry costs. 每个项目都产出整合方案：为 FDA 合规设计正确的美国实体架构，优化税务效率，并对市场进入成本提供清晰的财务预测。
510(k), PMA pathways. US Agent and Importer of Record entity setup. R&D tax credit optimization for clinical trials. 510(k)、PMA 审批路径。美国代理人和进口商实体设立。临床试验研发税收抵免优化。
ANDA/NDA filings. IP licensing structures for drug compounds. Transfer pricing for API and finished dosage imports. ANDA/NDA 申报。药物化合物 IP 许可架构。原料药和制剂进口的转让定价。
FSMA / FSVP compliance cost planning. Food facility registration entity requirements. Import duty and anti-dumping tax analysis. FSMA / FSVP 合规成本规划。食品设施注册实体要求。进口关税和反倾销税分析。
MoCRA registration requirements. DTC cross-border e-commerce tax compliance. Amazon FBA sales tax nexus planning. MoCRA 注册要求。DTC 跨境电商税务合规。Amazon FBA 销售税关联规划。
Structure your US presence to satisfy FDA requirements—US Agent, Importer of Record, Initial Importer, Owner/Operator—while optimizing for tax efficiency. Delaware C-Corp vs. LLC, subsidiary vs. branch, and holding company jurisdictions evaluated holistically. 设计满足 FDA 要求的美国存在——美国代理人、进口记录持有人、初始进口商、所有人/运营商——同时优化税务效率。全面评估特拉华 C-Corp vs. LLC、子公司 vs. 分支机构及控股公司法域。
Identify and document qualifying R&D expenditures related to FDA submissions—clinical trials, bioequivalence studies, stability testing, 510(k) preparation—to maximize federal and state R&D tax credits (Section 41/174). 识别和记录与 FDA 申报相关的合格研发支出——临床试验、生物等效性研究、稳定性测试、510(k) 准备——以最大化联邦和州研发税收抵免（Section 41/174）。
Design arm’s-length intercompany pricing for FDA-regulated products—APIs, finished goods, contract manufacturing services—that withstands IRS and foreign tax authority scrutiny while reflecting the unique cost structure of FDA compliance. 为 FDA 监管产品——原料药、成品、合同制造服务——设计符合独立交易原则的关联交易定价，经得起 IRS 和外国税务机关审查，同时反映 FDA 合规的独特成本结构。
Analyze HTS classification, Section 301 tariffs, anti-dumping/countervailing duties, and first sale valuation strategies for FDA-regulated imports from China and Asia-Pacific origins. 分析 HTS 分类、301 条款关税、反倾销/反补贴税，以及从中国和亚太地区进口 FDA 监管产品的首次销售估值策略。
Build comprehensive financial models covering FDA submission costs, facility registration fees, compliance infrastructure, and ongoing reporting obligations—integrated with tax projections across multiple structural scenarios. 构建全面财务模型，涵盖 FDA 申报费用、设施注册费、合规基础设施和持续报告义务——与多种架构方案的税务预测相整合。
Sales tax nexus analysis, marketplace facilitator obligations, and state-by-state compliance planning for FDA-regulated products sold through Amazon, Shopify, and direct-to-consumer channels. 销售税关联分析、市场促进者义务，以及通过 Amazon、Shopify 和 DTC 渠道销售 FDA 监管产品的各州合规规划。
Medical Devices医疗器械
Designed a Delaware subsidiary structure for a Shenzhen medical device manufacturer pursuing FDA 510(k) clearance. Identified $420K in qualifying R&D expenditures for tax credit claims, and structured the intercompany pricing to reduce effective tariff impact by 8% through first sale valuation. 为追求 FDA 510(k) 批准的深圳医疗器械制造商设计特拉华子公司架构。识别 42 万美元合格研发支出用于税收抵免申报，并通过首次销售估值将有效关税影响降低 8%。
Food & Beverage食品饮料
Structured a US import entity for a major Chinese food manufacturer to serve as FSVP Importer, optimizing the entity for both FDA facility registration requirements and Section 301 tariff mitigation. Annual compliance cost savings of $180K through entity consolidation. 为大型中国食品制造商构建美国进口实体作为 FSVP 进口商，同时优化实体以满足 FDA 设施注册要求和 301 条款关税缓解。通过实体整合实现年合规成本节约 18 万美元。
Cosmetics / E-Commerce化妆品/电商
Advised a Chinese beauty brand selling FDA-regulated cosmetics via Amazon US and Shopify on MoCRA registration, sales tax nexus in 14 states, and a Hong Kong holding structure that reduced overall tax leakage on US-bound inventory by 6%. 为通过 Amazon 美国和 Shopify 销售 FDA 监管化妆品的中国美妆品牌提供 MoCRA 注册、14 个州销售税关联及香港控股架构咨询，将美国库存的整体税务流失降低 6%。
Oil & Gas Equipment石油装备
Guided a publicly listed Shandong-based petroleum lifting equipment manufacturer—specializing in sucker rod pumps, screw pumps, and rodless oil production systems for crude oil, coalbed methane, and shale gas extraction—through US oilfield market entry. Leveraged the company’s existing API and ISO 9001 certifications to plan API Monogram compliance for the US entity, structured a Texas subsidiary for direct engagement with Permian Basin and Eagle Ford operators, and designed the intercompany transfer pricing for specialized lifting equipment exports. The entity was architected to serve as both the US commercial arm and the API certification holder, consolidating regulatory and commercial presence into a single tax-efficient structure under SAP-ERP integrated operations. 协助一家新三板上市的山东石油举升设备制造商——专注抽油泵、螺杆泵和无杆采油系统，覆盖原油、煤层气和页岩气开采——进入美国油田市场。利用企业现有 API 和 ISO 9001 认证规划美国实体的 API 标志合规，在德克萨斯设立子公司以直接对接 Permian Basin 和 Eagle Ford 产区运营商，并为特种举升设备出口设计关联交易转让定价。将实体架构设计为同时承担美国商业职能和 API 认证持有人角色，在 SAP-ERP 集成运营下将监管与商业存在整合为单一税务高效架构。
Pump & Water Systems / OEM水泵系统/代工
Advised a Ningbo-based pump manufacturer—producing circulator pumps, multistage centrifugal pumps, and submersible systems across 68 countries as an OEM partner for major US water technology brands—on establishing a US subsidiary. Designed the entity structure to support NSF/ANSI 61 certification for water-contact components, enabled the transition from pure OEM exporter to a US-present operation with direct distribution and after-sales support, and optimized the intercompany transfer pricing and service fee structure to minimize withholding tax exposure under the US-China treaty. 为一家宁波水泵制造商提供美国子公司设立咨询——该企业生产循环泵、多级离心泵和潜水泵系统，作为美国知名水处理品牌的 OEM 合作伙伴覆盖 68 个国家。设计实体架构以支持水接触组件的 NSF/ANSI 61 认证，推动从纯 OEM 出口商向具有直接分销和售后支持能力的美国本地运营的转型，并优化关联交易转让定价和服务费架构以在美中税收协定下最小化预提税风险敞口。